诺和诺德Novo Nordisk (NVO) 2012年年度报告「NYSE」.pdf

1、 novo nordisk annual report 2012Sustainable growth can it be done?Insulin in a tablet why is it so difficult?Diabetes an emergency in slow motionStrategy is all about choiceNovo Nordisks performance in 2012 is a result of important decisions made in recent years but there is more to the story22The p

2、rotein powerhouse20Diabetes an emergency in slow motion28Simple injectionsContentsAccomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlookOur business 15 Strategy is all about choice 20 Diabetes an emergency in slo

3、w motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet why is it so difficult?28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets one model 38 Sustainable growth can it be done?41 With every big opportunity comes a riskGovernance,

4、leadership and shares 44 Shares and capital structure 46 Corporate governance 49 Remuneration 52 Board of Directors 54 Executive ManagementFinancial,social and environmental statements 55 Consolidated financial,social and environmental statements104 Financial statements of the parent company109 Mana

5、gements statement and Auditors reportsAdditional information112 More information113 Product overviewThe Management review,as defined by the Danish Financial Statements Act(FSA),is found on pp 154 and 94.This Annual Report is published in both a Danish and an English language version.In the event of

6、any discrepancies,the Danish version shall prevail.Letter from the Chairman2012 was a very good year for Novo Nordisk.Both in terms of financial performance with reported sales up by 18%and net profit growth of 25%and progress in the companys research and development pipeline,which promises well for